Jia, Hejin
Wang, Zhenguang
Wang, Yao
Liu, Yang
Dai, Hanren
Tong, Chuan
Guo, Yelei
Guo, Bo
Ti, Dongdong
Han, Xiao
Yang, Qingming
Wu, Zhiqiang
Han, Weidong
Article History
Received: 27 February 2019
Accepted: 10 May 2019
First Online: 10 June 2019
Ethics approval and consent to participate
: Ahead of planned phase I clinical trials, TanCAR-T 19/22 cells were under compassionate use for this patient. The treatment for this patient was provided under the Declaration of Helsinki and approval of the Institutional Review Board at the Chinese PLA General Hospital and with informed consent.
: Written informed consent was obtained from the patient.
: The authors declare that they have no competing interests.